Patents by Inventor Theresa A. Branchek
Theresa A. Branchek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7132248Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: October 31, 2002Date of Patent: November 7, 2006Assignee: H. Lundbeck A/SInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Patent number: 7067277Abstract: This invention provides isolated nucleic acids encoding chimeric G proteins, vectors comprising nucleic acids encoding chimeric G proteins, cells comprising such vectors, processes of determining agonists and antagonists of mammalian G protein-coupled receptors utilizing chimeric G proteins, processes of determining compounds which bind to mammalian G protein-coupled receptors utilizing chimeric G proteins, processes for making a composition of matter which specifically binds to a mammalian G protein-coupled receptor utilizing chimeric G proteins, processes for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by a process of the invention utilizing chimeric G proteins, processes of identifying a ligand for a mammalian G protein-coupled receptor utilizing chimeric G proteins, and processes of screening a plurality of independent clones to identify and isolate a clone encoding a mammalian G protein-coupled receptor utilizing chiType: GrantFiled: December 23, 1999Date of Patent: June 27, 2006Assignee: H. Lundbeck A/SInventors: Kenneth A. Jones, Mary W. Walker, Joseph Tamm, Theresa A. Branchek, Christophe P. G. Gerald
-
Patent number: 7060449Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: November 18, 2002Date of Patent: June 13, 2006Assignee: H. Lundbeck A/SInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 7022489Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: December 3, 2001Date of Patent: April 4, 2006Assignee: H. Lundbeck A/SInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Publication number: 20060014242Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.Type: ApplicationFiled: November 12, 2004Publication date: January 19, 2006Inventors: Christophe Gerald, Richard Weinshank, Mary Walker, Theresa Branchek
-
Patent number: 6913892Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.Type: GrantFiled: October 29, 1999Date of Patent: July 5, 2005Assignee: H. Lundbeck A/SInventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6818445Abstract: This invention provides isolated nucleic acid molecules encoding a neuropeptide Y (NPY) Y5 receptor which hybridizes under high stringency conditions to a nucleic acid molecule of SEQ ID NO:3, vectors comprising such isolated nucleic acid molecules, and cells comprising such vectors.Type: GrantFiled: September 24, 2001Date of Patent: November 16, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Patent number: 6790656Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: June 4, 1998Date of Patent: September 14, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 6713265Abstract: The invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has structure (I). In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.Type: GrantFiled: September 27, 1999Date of Patent: March 30, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Publication number: 20030215823Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: October 31, 2002Publication date: November 20, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Patent number: 6645774Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.Type: GrantFiled: November 23, 1999Date of Patent: November 11, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Publication number: 20030166066Abstract: This invention provides an isolated nucleic acid encoding a mammalian 5-HT4B receptor and an isolated nucleic acid encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid encoding a mammalian 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid which encodes a mammalian or human 5-HT4B receptor, and pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.Type: ApplicationFiled: April 9, 2002Publication date: September 4, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Publication number: 20030162944Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.Type: ApplicationFiled: July 2, 2002Publication date: August 28, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Christophe Gerald, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6602888Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.Type: GrantFiled: November 22, 1999Date of Patent: August 5, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
-
Publication number: 20030129702Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: November 18, 2002Publication date: July 10, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P.G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 6586191Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: July 23, 1997Date of Patent: July 1, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Publication number: 20030082641Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: January 26, 2001Publication date: May 1, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20030082672Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: July 23, 1997Publication date: May 1, 2003Inventors: KELLI E. SMITH, DAVID LINEMEYER, CHRISTOPHE GERALD, THERESA BRANCHEK, RICHARD L. WEINSHANK, CARLOS FORRAY
-
Publication number: 20030027254Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: December 3, 2001Publication date: February 6, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20030022900Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.Type: ApplicationFiled: June 28, 2002Publication date: January 30, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig